Health Sciences Research Center (CICS), Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal. apo @ fcsaude.ubi.pt
Gynecol Obstet Invest. 2010;70(4):322-7. doi: 10.1159/000314023. Epub 2010 Oct 16.
Candida spp. are common causative agents of mucocutaneous infections. New therapeutic antifungal drugs are needed to treat chronic disease as these are frequently clinically resistant to azols. Chitosan, among other possible vehicles for active compounds, shows an added value as it appears to have intrinsic antimicrobial properties. The aim of the present study was to evaluate the anti-Candida activity of a medium-molecular-weight chitosan hydrogel (CH), to clarify its possible mechanism of action and to evaluate its cytotoxicity on human fibroblasts. CH antifungal activity was assessed according to CLSI reference M27-A3 protocol; its mechanism of action was investigated by flow cytometry, and its cytotoxicity was studied by MTT assay. CH demonstrated a full inhibition of C. tropicalis, C. krusei, C. guilliermondii and C. parapsilosis growth while impairing C. albicans and C. glabrata viability. Flow cytometry tests showed that CH acts by inducing primary lesion of the cytoplasmic membrane. However, CH showed no cytotoxic effect upon human fibroblasts cells. Resistant strains will require new therapeutic approaches. Chitosan being a good carrier and having itself anti-Candida activity seems to be a promising vehicle to be used for the treatment of mucocutaneous candidosis.
假丝酵母菌属是黏膜皮肤感染的常见病原体。由于这些病原体经常对唑类药物产生临床耐药性,因此需要新的治疗性抗真菌药物来治疗慢性疾病。壳聚糖作为活性化合物的可能载体之一,具有附加值,因为它似乎具有内在的抗菌特性。本研究旨在评估中分子量壳聚糖水凝胶(CH)的抗假丝酵母菌活性,阐明其可能的作用机制,并评估其对人成纤维细胞的细胞毒性。根据 CLSI 参考 M27-A3 方案评估 CH 的抗真菌活性;通过流式细胞术研究其作用机制,并通过 MTT 测定研究其细胞毒性。CH 完全抑制热带假丝酵母菌、克鲁斯假丝酵母菌、光滑假丝酵母菌和近平滑假丝酵母菌的生长,同时损害白假丝酵母菌和克柔假丝酵母菌的活力。流式细胞术试验表明 CH 通过诱导细胞质膜的原发性损伤起作用。然而,CH 对人成纤维细胞没有细胞毒性作用。耐药株将需要新的治疗方法。壳聚糖作为一种良好的载体,本身具有抗假丝酵母菌活性,似乎是一种有前途的治疗黏膜皮肤假丝酵母菌病的载体。